Apheresis for renal disease

Therapeutic Apheresis

Volumn 5, Issue 2, 2001, Pages 134-141

  Kaplan, Andre A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bone marrow transplantation; Glomerulonephritis; IgA nephropathy; Multiple myeloma; TTP HUS

Indexed keywords

ANTIBODY; AUTOANTIBODY; ENZYME; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY;

APHERESIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONFERENCE PAPER; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; GLOMERULONEPHRITIS; GLOMERULUS; GOODPASTURE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY DISEASE; NEPHROTOXICITY; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT PLANNING;

ADULT; AUTOIMMUNE DISEASES; BLOOD COMPONENT REMOVAL; HUMANS; KIDNEY DISEASES;

EID: 0035014787     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2001.005002134.x     Document Type: Conference Paper

References (117)

1. Plasmapheresis as a therapy in specific forms of acute renal failure
2. Therapeutic plasma exchange in renal disease
3. Therapeutic plasma exchange for renal disease
4. Therapy of anti-glomerular basement membrane disease: Analysis of prognostic significance of clinical, pathologic and treatment factors
5. Antiglomerular basement membrane antibody-mediated disease in the British Isles 1980-4
6. Plasma exchange in Goodpasture's syndrome
7. Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome
8. Plasma exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis
9. Plasmapheresis in rapidly progressive glomerulonephritis
10. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis
11. Plasmapheresis in the treatment of rapidly progressive glomerulonephritis
12. Plasmapheresis in treatment of acute oligoanuria in crescentic glomerulonephritis
13. Therapeutic plasma exchange in the treatment of rapidly progressive glomerulonephritis
14. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: A controlled multicenter study
15. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies
16. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis
17. Therapeutic plasma exchange for the treatment of rapidly progressive glomerulonephritis (RPGN)
18. Still a role for plasma exchange in rapidly progressive glomerulonephritis?
19. Effect of plasmapheresis as initial monotherapy in a case of anti-neutrophil cytoplasmic autoantiboy positive crescentic glomerulonephritis
20. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study
21. IgA nephropathy
22. Plasmapheresis in nephritis associated with Henoch-Schonlein purpura and in primary IgA nephropathy
23. Plasma exchange in primary IgA nephropathy and Henoch-Schonlein syndrome nephritis
24. Plasmapheresis in a patient with rapidly progressive idiopathic IgA nephropathy: Removal of IgA-containing circulating immune complexes and clinical recovery
25. Plasma exchange in progressive IgA nephropathy
26. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schonlein pupura nephritis in children
27. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis
28. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome
29. Focal segmental glomerulosclerosis in renal transplants
30. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children
31. How to deal with the hyperimmunized potential recipients
32. Renal transplantation following immunoadsorption in highly sensitized recipients
33. A controlled trial of plasmapheresis in the treatment of renal allograft rejection
34. Plasma exchange in acute renal allograft rejection
35. Effects of plasmapheresis in renal transplant rejection: A controlled study
36. Reversible severe vascular rejection after plasmapheresis
37. Nephrotoxic potential of bence jones proteins
38. Controlled plasma exchange trial in acute renal failure due to multiple myeloma
39. Management of myeloma kidney: An anti-light chain approach
40. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy
41. Improved survival in multiple myeloma with renal failure
42. Renal failure in multiple myeloma
43. Cryoglobulins: Properties, prevalence in disease and removal
44. Lymphoma, cryoglobulinemia and renal disease
45. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia
46. The effect of combination therapy (steroids, immunosuppressives and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic and vascular involvement
47. Acute renal failure in essential mixed cryoglobulinemia: Precipitation and reversal by plasma exchange
48. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange
49. Renal involvement in essential mixed cryoglobulinemia
50. Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis
51. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
52. Management of immune-mediated and paraproteinemic diseases by membrane plasma separation and cascade filtration
53. Cryofiltration as an alternative to plasma exchange: Plasma macromolecular solute removal without replacement fluids
54. Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia
55. Pathology of the kidney in Waldenstrom's macroglobulinemia: Study of sixteen cases
56. Multiple myeloma and Waldenstrom's macroglobulinemia: Unusual presentations
57. Treatment of Waldenstrom's macroglobulinemia by plasmapheresis
58. Rapidly progressive (crescentic) glomerulonephritis and monoclonal gammapathies
59. Plasmapheresis therapy in macroglobulinemia
60. Experience with large volume plasmapheresis in malignant paraproteinemia and immune disorders
61. Cascade filtration: Clinical application in 26 patients with immune complex and IgM mediated diseases
62. Hyperviscosity syndrome: Efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenstrom's type
63. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
64. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
65. Improved survival of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Clinical experience in 108 patients
66. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura
67. Escherichia coli 0157:H7 and the hemolytic-uremic syndrome
68. Escherichia coli and the hemolytic uremic syndrome
69. Hemolytic uremic syndrome - Then and now
70. Mitomycin-induced hemolytic-uremic syndrome: Successful treatment with corticosteroids and intense plasma exchange
71. Quinine sensitivity: A new cause of the hemolytic uremic syndrome
72. Adult hemolytic uremic syndrome: A review of 37 cases
73. Prognostic importance of vascular lesions in acute renal failure with microangiopathic hemolytic anemia (hemolytic uremic syndrome): Clinicopathologic study in 20 adults
74. Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome
75. The renal manifestations and outcome of thrombotic thrombocytopenic pupura/hemolytic uremic syndrome
76. Cancer associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry
77. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion
78. Successful treatment of cisplatin induced HUS with therapeutic plasma exchange
79. Cancer and drug associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
80. Therapeutic apheresis for cancer related hemolytic uremic syndrome
81. Complete response in severe thrombotic microangiopathy post bone marrow transplantation (BMT-TM) after multiple plasmaphereses
82. Extracorporeal treatment of thrombotic microangiopathy: A ten year experience
83. Recurrent hemolytic uremic syndrome in an adult renal allograft recipient: Current concepts and management
84. The epidemiology and clinical aspects of the hemolytic uremic syndrome in Minnesota
85. Escherichia coli and the hemolytic uremic syndrome
86. Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial
87. Plasma exchange in children with hemolytic-uremic syndrome at risk of poor outcome
88. The successful treatment of atypical hemolytic uremic syndrome with plasmapheresis
89. Combined plasmapheresis and hemodialysis treatment for severe hemolytic-uremic syndrome following Campylobacter colitis
90. Reversal of central nervous system involvement in hemolytic uremic syndrome by use of plasma exchange
91. Plasmapheresis in the management of acute systemic lupus erythematosus?
92. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus
93. Therapeutic plasmapheresis in systemic lupus erythematosus
94. Plasmapheresis in active lupus erythematosus: Effect on clinical, serum and cellular abnormalities. Case report
95. Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression
96. Randomized trial of plasma exchange in mild systemic lupus erythematosus
97. A randomized trial of plasma exchange in severe acute systemic lupus erythematosus: Methodology interim analysis
98. A controlled trial of plasmapheresis therapy in severe lupus nephritis
99. Plasmapheresis in a pregnancy complicated by acute systemic lupus erythematosus. Case report
100. Predictive value of clinical, laboratory, pathologic, and treatment variables in steroid/immunosuppressive resistant lupus nephritis
101. Apheresis for lupus erythematosus
102. Therapeutic plasma exchange and cyclosporine in the treatment of systemic lupus erythematosus
103. A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: Design of the LPSG trial
104. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus
105. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide
106. The Lupus Plasmapheresis Study Group: Rationale and updated interim report
107. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis
108. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance
109. Successful removal of antiphospholipid antibody during pregnancy using plasma exchange and low dose prednisolone
110. Plasma exchange and the anticardiolipin syndrome in pregnancy
111. The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A review of 31 patients
112. Catastrophic antiphospholipid syndrome: Response to repeated plasmapheresis over three years
113. Effective combination therapy of plasma exchange and subsequent cyclophosphamide pulses for catastrophic antiphospholipid antibody syndrome: A case report
114. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy related renal failure
115. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis
116. Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies-related scleroderma renal crisis treated with double-filtration plasmapheresis
117. Treatment of severe localized scleroderma by plasmapheresis - Report of three cases